Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A 24-week with possible extension prospective multicentre randomized double blind placebo-controlled 2-parallel group with a randomization 1:1 Phase 3 study to compare efficacy and safety of masitinib at 6 mgkgday to placebo in treatment of...

The objective is to compare the safety and efficacy of masitinib to placebo in patients with documented Smouldering or Indolent Systemic mastocytosis with severe handicap Primary endpoint: Cumulative response by patienthandicap

FieldValue
Modified
2020-04-04
Release Date
2018-08-03
Identifier
19624a9f-a2f1-440e-b5b0-9075e7c8bb3e
License
Public Access Level
Public